Sign In  |  Register  |  About Burlingame  |  Contact Us

Burlingame, CA
September 01, 2020 10:18am
7-Day Forecast | Traffic

  • Search Hotels in Burlingame

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pfizer (NY: PFE )

27.73 -0.03 (-0.09%)
Streaming Delayed Price Updated: 10:06 AM EST, Nov 5, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pfizer

< Previous 1 2
...
29 30 31 32 33 34 35 36 37
...
99 100 Next >
MarketBeat Week in Review – 2/12 - 2/16
Higher inflation readings dampened expectations for rate cuts, and a shortened trading week may get more volatile when many retail stocks report earnings 
Via MarketBeat
Topics Economy
Exposures Interest Rates
Pfizer's Expansion Sparks Boom for these Healthcare REITs
Via Benzinga
7 F-Rated Stocks to Sell for February 2024
The stock market is off to a good start and there are plenty of great names out there. So don't hold on to your F-rated stocks to sell. 
Via InvestorPlace
Pfizer's Mixed Bag: A Look At The Fourth Quarter 2023 Earnings Call - Main Takeaways
Pfizer Inc. (NYSE: PFE) recently held its fourth-quarter earnings call, revealing a year of contrasts for the pharmaceutical giant. While the company faced setbacks, particularly with its COVID-19... 
Via Benzinga
Topics Earnings
Exposures COVID-19 Financial
Behind the Scenes of Pfizer's Latest Options Trends
Via Benzinga
Unpacking the Latest Options Trading Trends in Pfizer
Via Benzinga
The 3 Biotech Stocks That Could Make Your February Unforgettable
After a blistering hot year of biotech M&A, we’ll see more of the same in 2024. That could be great news for these hot biotech stocks. 
Via InvestorPlace
Pfizer Invites Public to Register for Webcast of Pfizer Oncology Innovation Day
From Pfizer Inc.
Via Business Wire
The 7 Best Dividend Stocks to Buy in February 2024
The market is soaring and many sectors appear overvalued. Fortunately, these leading dividend stocks are still available at great prices. 
Via InvestorPlace
Global Fibromyalgia Treatment Market Expected to Reach $4.6 billion by 2032
EQNX::TICKER_START (NASDAQ:TNXP),(NYSE:PFE),(NYSE:LLY),(NYSE:ABBV),(NYSE:MRK) EQNX::TICKER_END 
Via FinancialNewsMedia
Global Fibromyalgia Treatment Market Expected to Reach $4.6 billion by 2032
From FN Media Group LLC
Via GlobeNewswire
Pfizer at 10-year support: Is it a massive buy opportunity?
As Pfizer's stock nears 10-year support at $26, with better-than-expected earnings despite declining COVID-19-related revenue, is now the time to buy? 
Via MarketBeat
Topics Earnings
Exposures COVID-19 Financial
7 Undervalued Dividend Stocks to Buy in February for High Total Returns
The undervalued dividend stocks could see serious growth before too long. Plus, they pay you to hold them while you wait. 
Via InvestorPlace
Pfizer Agrees To Pay $93M To Settle Lipitor Antitrust Lawsuit Despite Calling Allegations 'Factually And Legally Without Merit'
Pfizer has agreed to pay $93 million to settle an antitrust lawsuit related to its cholesterol drug Lipitor. 
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
Biden Boom: 7 Stocks to Buy if Democrats Win the Election in 2024
Election-proof your portfolio: these seven stocks could deliver significant gains if Biden wins the election in 2024. 
Via InvestorPlace
7 Must-Buy Pharma Stocks Amid the Weight Loss Drug Revolution
Obesity drug sales boomed in 2023 and will continue in 2024. That could make these weight loss stocks even more attractive. 
Via InvestorPlace
Carrick Therapeutics Announces First Patient Dosed in Phase 1b/2 Clinical Trial of Samuraciclib in Combination with Vepdegestrant in Patients with Advanced Breast Cancer
From CARRICK THERAPEUTICS LIMITED
Via GlobeNewswire
Anal Cancer Treatment Market Expected to Reach $1.63 Billion by 2030 as Latest Clinical Studies Focus on New Therapies
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:EXEL),(NYSE:PFE),(NASDAQ:BTAI),(NYSE:BMY) EQNX::TICKER_END 
Via FinancialNewsMedia
Wall Street's Most Accurate Analysts' Views On 3 Health Care Stocks Delivering High-Dividend Yields
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high... 
Via Benzinga
Anal Cancer Treatment Market Expected to Reach $1.63 Billion by 2030 as Latest Clinical Studies Focus on New Therapies
From FN Media Group LLC
Via GlobeNewswire
7 High-Yield Dividend Stocks for the Ultimate Retirement Portfolio
Discover seven high-yield dividend stocks for retirement across diverse sectors, including telecommunications, REITs, and pharmaceuticals. 
Via InvestorPlace
Topics Retirement
Exposures Pension
3 Blue-Chip Stocks Drowning in Earnings Despair
Investors should shy away from these companies after they delivered substandard financial results for the final months of last year. 
Via InvestorPlace
The 3 Best Biotech Stocks to Buy in February 2024
The best biotech stocks to buy offer consistent growth opportunities and resist the influence of singular drug successes. 
Via InvestorPlace
Contrarian Plays: 3 Stocks Going Against the Grain That Could Deliver Huge Gains
The conventional wisdom is that these stocks are going nowhere. But the conventional wisdom just might be wrong. 
Via The Motley Fool
A Look At Pharma ETFs After Q4 Earnings
The fourth-quarter results of the healthcare sector have been unimpressive, with earnings of companies that have reported so far down 17.7% despite 7% revenue growth. 
Via Talk Markets
Topics ETFs
The 7 Best Momentum Stocks You Can Purchase Today
If you’re looking for hot opportunities in the market, here are just a few of the best momentum stocks to buy today. 
Via InvestorPlace
Gene Therapy Player REGENXBIO's RGX-121 Marks Success In Trial, Yet Faces Challenges In A Crowded Market: Analyst
Insights from Wedbush analysts about the clinical effectiveness of REGENXBIO's RGX-202, market potential, and challenges posed by competitors like Sarepta Therapeutics and Pfizer. 
Via Benzinga
Super Bowl Commercials 2024: Complete List Of Super Bowl LVIII Ads And Companies Behind Them
The complete list of Super Bowl LVIII commercials and the companies behind them, including the stock tickers. 
Via Benzinga
2 Value Stocks With Monster Yields
These two low-priced large-cap stocks sport ginormous yields. 
Via The Motley Fool
7 Dividend Stocks to Buy at a 52-Week Low
Each of these dividend stocks has been down sharply in the last 12 months but has fundamental reasons that support a turnaround. 
Via InvestorPlace
< Previous 1 2
...
29 30 31 32 33 34 35 36 37
...
99 100 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 Burlingame.com & California Media Partners, LLC. All rights reserved.